Enoru-Eta Julius, Yengi Lilian G, He Xiaoyang, Kubik Joseph, Kao John, Scatina Joann
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research & Development, Collegeville, Pennsylvania 19426, USA.
Drug Metab Lett. 2010 Jan;4(1):31-8. doi: 10.2174/187231210790980444.
The present manuscript describes the development of a cell-based reporter transcriptional activation assay for evaluating induction of UGT1A1. A reporter construct (pGL-UGT1A1-Luc) encompassing the proximal promoter (nucleotide -254 to +38) and distal enhancer (-3483 to -3194) regions of the human UGT1A1 gene was generated by PCR cloning, and co-transfected with a previously generated PXR construct (pSG5-PXR) into HepG2 cells. The system was then validated using known ligands of PXR, rifampicin (RIF), clotrimazole (CLOT) sulfinpyrazone (SPZ) and phenobarbital (PB), which produced dose dependent induction of UGT1A1 luciferase activity by 4.4, 5.3, 4.7 and 3.7 fold, respectively, relative to the vehicle control, 0.1 % dimethylsulfoxide (DMSO). Aryl hydrocarbon receptor (AhR) ligands a-naphthoflavone (a-Naph), b-naphthoflavone (b-Naph) and 3-methylchloranthene (3-MC) increased UGT1A1 luciferase activity in a concentration dependent manner resulting in 17.2, 11.3 and 6.1 fold, respectively, at their highest concentrations, suggesting that endogenous AhR is also involved in the regulation of the UGT1A1 reporter construct in HepG2 cells. For comparison with transcriptional regulation of endogenous UGT1A1, 10 mM RIF, 50 mM SPZ, 10 mM CLOT, 4 mM 3-MC, 10 mM b-Naph and 25 mM a-Naph also induced UGT1A1 mRNA in human primary hepatocytes by 2.5, 2.8, 3.2, 3.7, 3.9 and 4.3 fold, respectively. In summary, by co-transfecting the UGT1A1 reporter and PXR constructs into HepG2 cells, we have developed a cellular model for evaluating induction of UGT1A1. Data from the reporter gene assay correlated with that generated in human primary hepatocytes. Based on these data, we suggest that this reporter gene assay can be used as a screening tool in the early stages of drug discovery, to evaluate potential induction of UGT1A1 by new chemical entities and to aid in lead selection and optimization.
本手稿描述了一种用于评估UGT1A1诱导作用的基于细胞的报告基因转录激活测定法的开发。通过PCR克隆产生了一个报告基因构建体(pGL-UGT1A1-Luc),其包含人UGT1A1基因的近端启动子(核苷酸-254至+38)和远端增强子(-3483至-3194)区域,并与先前产生的PXR构建体(pSG5-PXR)共转染到HepG2细胞中。然后使用已知的PXR配体利福平(RIF)、克霉唑(CLOT)、磺吡酮(SPZ)和苯巴比妥(PB)对该系统进行验证,相对于载体对照0.1%二甲亚砜(DMSO),它们分别使UGT1A1荧光素酶活性产生剂量依赖性诱导,倍数分别为4.4、5.3、4.7和3.7倍。芳烃受体(AhR)配体α-萘黄酮(α-Naph)、β-萘黄酮(β-Naph)和3-甲基氯蒽(3-MC)以浓度依赖性方式增加UGT1A1荧光素酶活性,在其最高浓度时分别导致17.2、11.3和6.1倍的增加,这表明内源性AhR也参与了HepG2细胞中UGT1A1报告基因构建体的调节。为了与内源性UGT1A1的转录调节进行比较,10 mM RIF、50 mM SPZ、10 mM CLOT、4 mM 3-MC、10 mM β-Naph和25 mM α-Naph也分别使原代人肝细胞中的UGT1A1 mRNA诱导了2.5、2.8、3.2、3.7、3.9和4.3倍。总之,通过将UGT1A1报告基因和PXR构建体共转染到HepG2细胞中,我们开发了一种用于评估UGT1A1诱导作用的细胞模型。报告基因测定的数据与原代人肝细胞中产生的数据相关。基于这些数据,我们建议该报告基因测定可作为药物发现早期阶段的筛选工具,用于评估新化学实体对UGT1A1的潜在诱导作用,并有助于先导化合物的选择和优化。